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Abstract
Tissue localization of gene expression is increasingly important for accurate interpretation of large scale datasets from
expression and mutational analyses. To this end, we have (1) developed a robust and scalable procedure for generation of
mRNA hybridization probes, providing .95% first-pass success rate in probe generation to any human target gene and (2)
adopted an automated staining procedure for analyses of formalin-fixed paraffin-embedded tissues and tissue microarrays.
The in situ mRNA and protein expression patterns for genes with known as well as unknown tissue expression patterns were
analyzed in normal and malignant tissues to assess procedure specificity and whether in situ hybridization can be used for
validating novel antibodies. We demonstrate concordance between in situ transcript and protein expression patterns of the
well-known pathology biomarkers KRT17, CHGA, MKI67, PECAM1 and VIL1, and provide independent validation for novel
antibodies to the biomarkers BRD1, EZH2, JUP and SATB2. The present study provides a foundation for comprehensive in situ
gene set or transcriptome analyses of human normal and tumor tissues.
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Introduction
Precise and specific tissue localization of gene expression is
instrumental for correct interpretation of transcriptome data from
complex tissues such as patient tumors. The rapid accumulation of
exome mutation data from tumors also yields novel putative
therapeutic targets, and it is therefore valuable to investigate tissue
gene expression to predict effects and side effects of novel cancer
therapies. Specificity validation of diagnostic and therapeutic
antibodies is another application where in situ gene expression
analyses could contribute essential knowledge. To make optimal
use of such in situ gene expression analyses in cancer biology, one
needs (1) methods for facile and efficient generation of probes to
any gene target, and (2) automated and robust procedures for
staining of formalin-fixed paraffin-embedded (FFPE) tissues and
tissue microarrays (TMAs).
In situ hybridization (ISH) techniques employ labeled RNA
probes to analyze the expression and localization of specific
mRNA transcripts in tissues at cell type resolution. Such probes
are typically generated by in vitro transcription from plasmid or
RT-PCR products in the presence of a hapten conjugated base
such as digoxigenin-UTP. After hybridization, the bound probes
are detected by chromogenic anti-hapten immunohistochemistry.
Whereas frozen tissue sections are most frequently used in mRNA
ISH, archival FFPE tissues and tissue microarrays can also be
employed [1]. As mRNA ISH is technically difficult and
encompasses many experimental steps, several different automa-
tion formats have been developed. The Tecan GenePaint system is
an open robotic system that has successfully been used to chart the
mouse transcriptome in frozen tissues [2,3]. Briefly, the prehy-
bridization, hybridization and signal detection reactions are
performed in a flow-through chamber where an automated
solvent system adds different solutions in parallel. This system
together with the detection technology enables a daily throughput
of up to two hundred slides [4]. Proteome-wide efforts have
already demonstrated the feasibility of large scale FFPE immuno-
staining [5,6]. Correlating protein and mRNA expression will
provide an independent validation tool for both immunohisto-
chemistry (IHC) and ISH, and enable the discovery of false
positives of either method.
To obtain a flexible way to analyze tissue expression of large
gene sets in FFPE tissue microarrays, we created a simple and
scalable PCR-based procedure for generation of mRNA probes to
any target gene in the same cDNA library and further developed
an automated staining system, where 48 genes can be processed in
48 tissues or TMAs in a single run. We then validated the
specificity and scalability of this approach by parallel ISH and
IHC targeting well-known biomarkers in pathology. Finally, we
demonstrate the specificity of antibodies to novel tissue-specific or
cancer biomarkers using in situ hybridization.
Results
Technology optimization
Seventeen genes were chosen to represent well established
pathology biomarkers or novel tissue-specific or cancer biomarkers
PLoS ONE | www.plosone.org 1 March 2012 | Volume 7 | Issue 3 | e32927discovered within the Human Protein Atlas project [5]. These
included bromodomain containing 1 (BRD1), chromogranin-A
(CHGA), histone-lysine N-methyltransferase (EZH2), family with
sequence similarity 174 member B (FAM174B), glutamate
decarboxylase 1 (GAD1), janus kinase 3 (JAK3), junction
plakoglobin (JUP), keratin 17 (KRT17), v-yes-1 Yamaguchi
sarcoma viral related oncogene homolog (LYN), mix1 homeo-
box-like 1 (MIXL1), antigen Ki-67 (MKI67), phosphodiesterase 6A
(PDE6A), platelet endothelial cell adhesion molecule 1 (PECAM1),
protein tyrosine phosphatase type C (PTPRC), special AT-rich
sequence-binding protein 2 (SATB2), villin1 (VIL1) and zinc finger
protein 473 (ZNF473). Desired PCR products and RNA probes
were obtained for all genes (Figure S1).
We next determined whether RNA probe length affects
sensitivity or specificity of ISH signals using two different
approaches. In the first approach, RNA probes for CHGA and
KRT17 were fragmented in duplicate using alkaline- and metal
ion-catalyzed methods to investigate if shorter probe length would
give a higher signal due to better tissue penetration. Both protocols
were adapted for use with DIG-UTP-labeled RNA probes. No
significant difference in signal could be seen between fragmented
and unfragmented probes when evaluating staining in normal
colon, kidney, liver, spleen and tonsil (data not shown). The second
approach was to investigate whether longer probes would have an
impact on ISH signal. Three different probes targeting PDGFRB
(platelet-derived growth factor receptor beta) with lengths of
500 bp, 1000 bp and 1500 bp were generated. No significant
difference in signal between the probe lengths could be seen when
evaluating staining in kidney glomeruli, however the background
was increased for 1000 bp and 1500 bp probes when comparing
sense and antisense RNA probes (data not shown) [7].
Adoption of the GenePaint system for human tissue
arrays
To facilitate a large-scale approach, optimization of proteinase
K concentration was performed. Three genes with various
expression levels, PDGFRB, KRT17 and beta actin (ActB), were
chosen and evaluated on a tissue microarray with normal colon,
kidney, liver, spleen and tonsil. Concentrations tested were 2.5, 5,
10, 20, 40, 60, 80 and 100 mg/ml. For ActB a concentration of
40 mg/ml was sufficient to provide clear and distinct signals
without affecting tissue morphology. For KRT17 and PDGFRB,a
proteinase K concentration of 60 mg/ml was optimal when
comparing all the different tissues on the array and was therefore
chosen for further experiments. To visualize genes expressed at
low levels, double cycles of tyramide-based signal amplification
was introduced. Furthermore, the importance of fresh tissue
sections has been ascertained since weak or no signal was seen for
tissue sections older than 3 weeks (data not shown).
Validation of ISH staining on tissue arrays
Consecutive tissue sections were stained using sense probe ISH,
antisense probe ISH and immunohistochemistry to compare the
gene expression on the mRNA and protein level. For a subset of
the analyzed genes (CHGA, KRT17, LYN, MKI67, PDE6A,
PECAM1, PTPRC and VIL1), immunohistochemistry-based pro-
tein expression patterns are well known and established. These
targets were used to compare the expression of protein and the
corresponding transcripts for validation of the scalable ISH
procedure. The intermediate filament protein KRT17 was, as
expected, highly expressed in a wide selection of differentiated
epithelial cells, as demonstrated by staining of the tonsil (Figure 1,
A–C and Figure S3) and in bronchus (Figure S3). CHGA, a
Figure 1. Validation of scalable in situ hybridization by parallel immunohistochemistry of pathology biomarkers on tissue arrays.
ISH signals are seen as blue/purple staining with nuclei counterstained in methyl green, whereas IHC signals are in brown with hematoxylin
counterstain. A–C: Keratin 17 (KRT17) in tonsil, D–F: Chromogranin A (CHGA) in colon, G–I: Ki-67 (MKI67) in colon, J–L: Platelet endothelial cell adhesion
molecule 1 (PECAM1) in placenta, M–O: Villin-1 (VIL1) in colon. Tissue arrays were hybridized with sense control probes (A, D, G, J, M), antisense probes
(B, E, H, K, N), or immunostained with antibodies (C, F, I, L, O) targeting the respective transcripts or protein products. All images were derived from
slides scanned with a 406objective.
doi:10.1371/journal.pone.0032927.g001
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in neuroendocrine cells of the gut (Figure 1, D–F), in pancreatic
islets and endocrine organs such as the parathyroid (Figure S3).
The well characterized proliferation marker Ki-67 is expressed in
G1, S, G2 and M stages of the cell cycle and often used to assess
proliferating cells within tumors. Proliferating cells in the base of
normal colonic crypts (Figure 1, G–I), in anal vulva and in tonsil
(Figure S3) are shown. The ISH signal for Ki-67 was localized to
specific regions in the nucleus in agreement with data from the
mouse [8]. PECAM1 was expressed in the endothelial cells in most
organs, exemplified by the richly vascularized placenta (Figure 1,
J–L), endometrium (pre menopause) and lymph node (Figure S3).
VIL1 is a protein expressed in the brush border of epithelia and as
such highly expressed in kidney tubules and glandular cells of the
gastrointestinal tract, such as the colon (Figure 1, M–O), appendix
and duodenum (Figure S3). Furthermore, for CHGA, PECAM1
and VIL1, two independent RNA probe pairs (Table S1) were used
for cross validation of probe specificity. The tissue and cellular
distribution pattern of expression for both mRNA and protein
were similar for these five genes, confirming the sensitivity and
specificity of automated in situ hybridization on FFPE TMAs. For
PDE6A, IHC showed staining in alveoli, skeletal muscle, bronchus
and cells in the renal glomeruli. mRNA and protein correlation
was only seen in two cases of skeletal muscle. Established
antibodies for LYN and PTPRC showed distinct membranous
and cytoplasmic staining in lymphoid tissues and glandular cells of
the gastrointestinal tract, and selective cytoplasmic staining in
lymphoid tissue, respectively. No correlation was seen between
protein and mRNA expression (Figure S5). For PTPRC, the lack of
ISH staining was cross validated with two independent RNA
probe pairs (Table S1).
Validation of novel antibody biomarkers by ISH on tissue
arrays
The antibody-derived expression in the Human Protein Atlas
project suggested either a tissue-specific expression or clinical
usefulness in cancer diagnostics or therapy for the novel putative
biomarkers BRD1, EZH2, FAM174B, GAD1, JAK3, JUP, MIXL1,
SATB2 and ZNF473. Therefore, analysis of their in situ mRNA and
protein expression in normal tissues could provide validation of
antibody specificity. BRD1 is known by immunohistochemistry to
be expressed in Purkinje and neuronal cells in CNS, cells in
seminiferus ducts in testis, glandular cells in prostate, adrenal
gland and appendix, and macrophages in lung, which was
confirmed by ISH (Figure 2, A–C and Figure S4). EZH2 is a
potential cancer biomarker as overexpression of the nuclear
protein is seen in a variety of aggressive cancers, including breast
cancer, prostate cancer and glioblastoma multiforme [9]. Gene
expression was found on both transcript (cytoplasmic staining) and
protein (nuclear staining) in glandular cells in appendix (Figure 2,
D–F), duodenum and fallopian tube (Figure S4), cells in
seminiferus ducts in testis and myocytes in heart muscles. JUP
was suggested by IHC to be a tissue-specific biomarker expressed
in adnexal and epidermal cells of the skin, which was confirmed by
ISH (Figure 2, G–I) and in squamous epithelial cells of the tonsil
(Figure S4). SATB2 is a novel biomarker for colorectal cancer
[10], where gene expression profiling has demonstrated association
of transcriptional downregulation with metastasis and poor
Figure 2. Validation of potential tissue-specific and cancer antibody biomarkers by in situ hybridization on tissue arrays. ISH signals
are seen as blue/purple staining with nuclei counterstained in methyl green, whereas IHC signals are in brown with hematoxylin counterstain. A–C:
Bromodomain containing 1 (BRD1) in adrenal gland, D–F: Histone-lysine N-methyltransferase (EZH2) in appendix (nuclear and cytoplasmic staining for
protein and mRNA, respectively), G–I: Junction plakoglobin (JUP) in skin, J–L: Special AT-rich sequence-binding protein 2 (SATB2) in colon (nuclear and
cytoplasmic staining for protein and mRNA, respectively). Tissue arrays were hybridized with sense control probes (A, D, G, J), antisense probes (B, E,
H, K), or immunostained with antibodies (C, F, I, L) targeting the respective transcripts or protein products. All images were derived from slides
scanned with a 406objective.
doi:10.1371/journal.pone.0032927.g002
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glandular cells of the lower gastrointestinal tract, including colonic
crypt cells (Figure 2, L). Concomitant array ISH confirmed
SATB2 transcript expression in cytoplasm restricted to the
epithelium of the appendix, colon (Figure 2, J–K) and rectum
(Figure S4), but not other organs. For validation of these four novel
biomarkers, two independent RNA probe pairs were used for each
gene (Table S1). GAD1 showed similar ISH and IHC staining in
Purkinje cells and cells in the molecular layer of the cerebellum,
but no correlation was seen in other tissues. The specificity of the
novel antibodies to FAM174B, JAK3, MIXL1 and ZNF473 could
not be verified by ISH (Figure S5). For JAK3, the lack of ISH
staining was cross validated with two independent RNA probe
pairs but for FAM174B, MIXL1 and ZNF473, only one probe pair
could be designed due to either too short protein coding regions or
too high homology with other genes (Table S1).
Parallel analyses of SATB2 protein and transcript
expression on FFPE colorectal cancer arrays
Protein and mRNA expression of SATB2 was assessed in
colorectal cancers using an array encompassing 60 primary tumors
in duplicate. Annotation was performed based on a three-grade
scale. One pair did not contain tumor tissue, and of the remaining
59 samples, 44 showed complete concordance between IHC and
ISH expression in glandular cells (Figure 3). Twelve showed semi
concordance as staining was observed but with different intensities,
whereas 3 samples displayed no correlation. Agreement between
protein and mRNA expression pattern was observed in a total of
56 samples (Cohen’s kappa test, k=0.68).
Discussion
Scaling ISH approaches to gene set or exome-wide analyses
requires pipelines for probe synthesis, hybridization, analysis and
annotation. Whereas much ground work has been performed in
the framework of large mouse transcriptome studies on frozen
tissues, modifications are necessary for successful and reproducible
ISH in FFPE materials. For facile probe synthesis, we conclude
that careful informatics combined with the use of a pooled human
cDNA library (MegaMan) entails a high first-pass success rate in
probe template generation. This cDNA library encompasses
mRNA from 32 human tissues and 34 human cancer cell lines
ensures a good representation of transcripts with diverse
expression levels and splice variants. In parallel projects, this
approach has successfully been used to generate a total of 700
probes with a first-pass success rate of .95% (data not
shown).Essential factors for successful staining that differ from
previously published procedures employing frozen tissues were the
use of freshly sectioned tissue, since weak or no staining was
observed for older FFPE tissue sections possibly due to oxidation of
RNA on the exposed surface or unsatisfactory fixation conditions
affecting RNA quality, a higher concentration of proteinase K,
and two cycles of tyramide biotin-based signal amplification.
Although the latter may result in slightly higher background levels,
it is in our experience a convenient way to increase signal intensity.
The specificity and sensitivity of ISH was thoroughly evaluated
by staining of consecutive sections from the same TMAs
encompassing ,40 normal tissue types in the human body. The
ISH and IHC staining patterns of KRT17, CHGA, MKI67,
PECAM1 and VIL1 were identical across tissue types, a selection
Figure 3. Validation of SATB2 antibody by in situ hybridization in a selection of arrayed colorectal cancers. ISH signals are seen as
blue/purple staining with nuclei counterstained in methyl green, whereas IHC signals are in brown with hematoxylin counterstain. Tissue arrays were
hybridized with sense control probe (A, D, G, J), antisense probe (B, E, H, K) or immunostained with antibody (C, F, I, L). All images were derived from
slides scanned with a 406objective.
doi:10.1371/journal.pone.0032927.g003
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thus providing strong validation of the ISH approach. This high
degree of concordance is in agreement with previous observations
from mouse transcriptome projects. However, a much needed
improvement to enable efficient data mining of ISH and IHC is a
standardized ontology for annotation of human tissues, in analogy
to the EMAP mouse anatomy ontology [3].
Antibody sensitivity and specificity is a major concern in
immunohistochemistry, especially in large scale projects where
numerous antibodies are being produced towards targets with
unknown expression patterns. Specificity validation of antibodies
to diagnostic grade may be performed by obtaining highly similar
staining pattern with an antibody raised to a different epitope of
the same antigen [6], loss of signal in knock-out mice or other
model organism, or highly similar staining pattern with in situ
hybridization. We here demonstrate the feasibility of the latter
approach at organism scale in the human, as TMAs encompassing
virtually all normal tissues can be analyzed in one single
experiment. We were able to verify the specificity of novel
antibodies to BRD1, EZH2, JUP and SATB2, with two
independent RNA probe pairs, confirming that ISH can provide
independent specificity validation. A selection of representative
samples is seen in Figure 2 and Figure S4. In parallel experiments,
we were unable to confirm specificity of the novel antibodies to
FAM174B, JAK3, MIXL1 and ZNF473 (Figure S5). The semi-
correlation between mRNA and protein expression for GAD1 and
PDE6A can be due to either antibody specificity or differences in
transcriptional and translational processes. The lack of correlation
between mRNA and protein expression for LYN and PTPRC can
be due to biological and technical reasons. The antibodies for LYN
and PTPRC are targeting all known isoforms of the proteins and
the RNA probe pairs are located in regions which are present in all
known transcripts. Also for PTPRC, two independent RNA probe
pairs were used, demonstrating lack of ISH staining between inter
TMA replicates. We therefore believe that the lack of correlation
between mRNA and protein expression is most likely due to
biological reasons, such as post-transcriptional, translational and
post-translational modifications affecting the levels of mRNA and
protein. Also, mRNA decay and protein half-life could have an
impact on mRNA and protein correlation. Other sources of
discrepancy between IHC and ISH could be lack of sensitivity or
specificity in either one of the approaches; this enables
interpretation of concordant staining patterns as supportive of
antibody specificity and discordant patterns as lack of specificity.
In large scale efforts, antibodies with concordant ISH staining
patterns should be prioritized for further analyses as opposed to
antibodies with discordant or lacking ISH staining.
SATB2, a nuclear matrix-associated transcription factor and a
member of the family of special AT-rich binding proteins, has
recently been shown to be expressed in normal cells of the lower
gastrointestinal tract and in cancer cells of colorectal origin. Due to
the highly specific nuclear expression pattern in normal and
malignant cells of the gastrointestinal tract, SATB2 protein
expression was suggested as a clinically useful diagnostic
biomarker for colorectal cancers, the third most commonly
diagnosed cancer in the world [10]. Cohen’s Kappa test was
performed to determine the agreement between IHC and ISH
staining, demonstrating good inter-rater reliability. The scalable
technology presented here also enables gene set expression
analyses in human tissue arrays. We envision that the tyrosine
kinome, tyrosine phosphatome, other genes in cancer pathways,
along with a multitude of novel candidate cancer genes derived
from exome and genome sequencing constitute prime targets for
large scale in situ hybridization based characterization. We propose
that comprehensive and systematic mapping of the expression in
situ in normal and malignant human tissues at cell type resolution
will provide valuable knowledge, especially in cancer drug
development as the results can aid in predicting effects, guide
repositioning of available targeted drugs, and help predict
response to drugs that inhibit several different molecular targets.
It also provides the technical foundation for transcript expression
mapping of human protein-encoding genes, and potentially also
other RNA species, in systematic whole-genome approaches.
Materials and Methods
Ethics statement
The use of HPA tissue arrays in this study is covered by the
HPA ethical permit (EPN Uppsala 2002/577, 2005/338) and
ethical permit to the investigators (EPN Uppsala 2007/116). The
identities of arrayed tissue samples are not known to the
investigators, nor will they be release into the public domain.
Probe generation
The probe generation procedure is outlined in Figure S2. We
developed an in-house software that selects transcript regions
suitable for hybridization probe design in the genes of interest by
minimizing homology with transcripts of other genes in the human
RefSeq transcriptome, ensuring that the probe sequences are
present in RefSeq transcripts of the gene of interest, and including
regions to span exon boundaries. Two independent PCR primer
sets for amplification of 500–600 nt products were generated for
each gene using Primer3 [12]. A T7 promoter sequence (59-
GCGTAATACGACTCACTATAGGG-39) was incorporated in
the 59-end of the forward or reverse primer, respectively, to
generate the sense or antisense riboprobe template. All primer
pairs used in probe generation are summarized in Table S1.
Stratagene’s MegaMan human transcriptome library, a collec-
tion of cDNA created using mRNA from 32 human tissues and 34
human cancer cell lines, was used for PCR (www.genomics.agilent.
com). Each reaction contained 2 ml1 0 6PCR buffer (166 mM
(NH4)2SO4, 670 mM Tris pH 8.8, 100 mM 2-mercaptoethanol,
67 mM MgCl2), 2 ml dNTPs (10 mM, GE Healthcare, Uppsala,
Sweden), 1.2 ml DMSO (Sigma-Aldrich, St. Louis, MO, USA),
0.4 ml forward primer (50 mM, Sigma-Aldrich), 0.4 ml reverse
primer (50 mM, Sigma-Aldrich), 0.2 ml Taq polymerase (5 U/ml,
Invitrogen, Carlsbad, CA, USA), 1 ml MegaMan human tran-
scriptome library (160 ng/ml, (Agilent Technologies, Santa Clara,
CA, USA)) and MilliQ water to a volume of 20 ml. The
touchdown PCR conditions included annealing temperatures
ranging from 64uCt o5 7 uC; 96uC for 2 min; 3 cycles of 96uC
for 10 s, 64uC for 10 s and 70uC for 30 s; 3 cycles of 96uC for 10 s,
61uC for 10 s and 70uC for 30 s; 3 cycles of 96uC for 10 s, 58uC
for 10 s and 70uC for 30 s; 41 cycles of 96uC for 10 s, 57uC for
10 s and 70uC for 30 s, and a final extension for 5 min at 70uC.
The PCR products were run on a 1.25% agarose gel for product
size confirmation. Sense and antisense riboprobes labeled with
digoxigenin were generated by in vitro transcription of PCR
products with DIG RNA labeling mix (Roche, Rotkreuz,
Switzerland) in a total reaction volume of 5 ml. One mg of each
RNA probe was run on a 6% TBE-Urea gel (Invitrogen) for size
confirmation. Stocks were made by diluting RNA probes with
MilliQ water to 200 ng/ml and stored in 280uC. Probe working
solutions of 20 ng/ml were made from stock solutions and stored in
220uC.
RNA probes were fragmented using two different approaches.
For alkaline-catalyzed fragmentation, giving fragments ranging
from 50–150 bp, RNA probes were digested with 0.2 M sodium
RNA Hybridization on Tissue Microarrays
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calculated by t=L02Lf/kL0Lf, where t is incubation time in
minutes, L0 and Lf are initial and final lengths of the probe in kb,
and k is the rate constant for hydrolysis (approximately
0.11 kb
21min
21). The reactions were stopped by adding sodium
acetate (pH 4.7) and samples were ethanol precipitated [13]. One
mg of each RNA probe was run on a 6% TBE-Urea gel for size
confirmation. For metal ion-catalyzed fragmentation, giving
fragments between 60–200 bp, RNA probes were incubated with
100 mM zinc chloride in 100 mM Tris-HCl (pH 7) at 70uC for
15 min. The reactions were stopped with 0.5 M EDTA (pH 8)
[14]. One mg of each RNA probe was run on a 6% TBE-Urea gel
for size confirmation.
Tissue preparation
The tissue arrays used were the standard arrays utilized for
immunohistochemistry in the Human Protein Atlas project (www.
proteinatlas.org). These arrays encompass triplicate 1-mm cores of
48 different types of non-malignant human tissue [15] and
duplicate 1-mm cores of primary colorectal cancer [10]. Tissue
microarrays with FFPE tumor and normal tissues were sectioned
to 6 mm and mounted on Superfrost Plus microscope slides.
In situ hybridization
Tissue sections were dewaxed in xylene, followed by hydration
in a graded ethanol series (100%, 95% and 80%, 3 min in each).
The hybridization was automated using Tecan GenePaint (Tecan
Ag, Ma ¨nnedorf, Switzerland) essentially as described [2,4,16]. All
procedures were performed at room temperature unless otherwise
stated. Briefly, endogenous peroxidase activity was blocked in
0.7% H2O2 in methanol, followed by deproteinization in 0.2 M
HCl and digestion by 60 mg/ml proteinase K (Roche). The tissue
sections were pre-hybridized in hybridization buffer (Ambion,
Foster City, CA, USA) without probe for 30 min and then
incubated with 200 ng/ml digoxigenin-labeled riboprobe for
4 hours at 64uC. After hybridization, tissue sections were washed
in 56saline-sodium citrate (SSC), 50% formamide and 0.16SSC.
To detect bound probe, an anti-digoxigenin antibody (150 U/ml,
Roche) conjugated to horseradish peroxidase was added. After five
washes in blocking buffer, a tyramide biotin amplification step was
performed to increase the in situ detection sensitivity (Perkin
Elmer, Waltham, MA, USA). The deposited biotin was detected
by alkaline phosphatase-conjugated neutravidin (2 mg/ml, Ther-
moScientific, Waltham, MA, USA), which cleaves the chromo-
genic substrate nitroblue tetrazolium (NBT) 5-bromo-4-chloro-3-
indolyl phosphate (BCIP) to produce a blue/purple precipitate at
the site of hybridization. After 30 min development time, the
chromogenic reaction was stopped by incubating the tissue
sections in a buffer containing EDTA, followed by fixation in
4% PFA. Nuclei were counterstained with 2% methyl green and
the slides were dehydrated in graded alcohols and mounted in a
resin-based medium.
Immunohistochemistry
Briefly, slides were deparaffinized in xylene, hydrated in graded
alcohols and blocked for endogenous peroxidase in 0.3%
hydrogen peroxide diluted in 95% ethanol. For antigen retrieval,
a decloaking chamber (Biocare Medical, Walnut Creek, CA; USA)
was used. Slides were immersed and boiled in citrate buffer, pH6
(Lab Vision, Va ¨rmdo ¨, Sweden) for 4 min at 125uC and then
allowed to cool to 90uC. Automated IHC was performed
essentially as described [17], using an Autostainer 480 instrument
(Lab Vision). Tissue sections were incubated with primary
antibodies (Table S2) and a dextran polymer visualization system
(UltraVision LP HRP polymer, Lab Vision) for 30 min each at
room temperature and slides were developed for 10 min using
diaminobenzidine (Lab Vision) as chromogen. All incubations
were followed by a rinse in wash buffer (Lab Vision). Slides were
counterstained in Mayer’s hematoxylin (Histolab, Gothenburg,
Sweden) and cover slipped using Pertex (Histolab) as mounting
medium. Incubation with 16 PBS instead of primary antibody
served as negative control.
Annotation of ISH and IHC tissues
The Aperio ScanScope CS Slide Scanner system (Aperio
Technologies, Vista, CA, USA) was used to digitize whole-slide
images of ISH and IHC arrays at 40-fold magnification. The
intensity of ISH and IHC staining was manually evaluated and
scored using an annotation system similar to that described in [18]
with a three grade scale; where 0 denotes absence of signal, 1
presence of weak to moderate signal and 2 presence of strong
signal. Cohen’s Kappa test was used to determine the agreement
between ISH and IHC.
Supporting Information
Figure S1 Generation of PCR product and RNA probes.
(A) PCR products (200 ng/well) were separated on a 1.25%
agarose gel. The expected band sizes were observed in all cases.
Lanes 1 and 21; 1 kb DNA ladder, lanes 20 and 38; negative
controls, lanes 2 and 3; sense and antisense for BRD1 (566 bp),
lanes 4 and 5; CHGA (546 bp), lanes 6 and 7; EZH2 (534 bp),
lanes 8 and 9; JUP (517 bp), lanes 10 and 11; KRT17 (510 bp),
lanes 12 and 13; MKI67 (533 bp), lanes 14 and 15; PECAM1
(528 bp), lanes 16 and 17; SATB2 (505 bp), lanes 18 and 19; VIL1
(514 bp), lanes 22 and 23; FAM174B (228 bp), lanes 24 and 25;
Gad1,(401 bp), lanes 26 and 27; JAK3 (505 bp), lanes 28 and 29;
LYN (510 bp), lanes 30 and 31; MIXL1 (402 bp), lanes 32 and 33;
PDE6A (568 bp), lanes 34 and 35; PTPRC (555 bp), and lanes 36
and 37; ZNF473 (516 bp). (B) RNA probes (1 mg/well) were
separated on a 6% TBE-Urea gel. The expected band sizes were
observed in all genes. Lanes 1, 14, 22 and 34; 0.1–2 kb RNA
ladder, lanes 13 and 40; negative controls, lanes 2 through 39;
same loading scheme as DNA gel in (A).
(TIF)
Figure S2 Probe generation procedure. Schematic repre-
sentation of the procedure.
(TIF)
Figure S3 Representative samples of concordant data
for the validation genes. ISH signals are seen as blue/purple
staining with nuclei counterstained in methyl green, whereas IHC
signals are in brown with hematoxylin counterstain. Keratin 17
(KRT17) in bronchus (left panel) and cervix, uterine (right panel);
Chromogranin A (CHGA) in pancreas (left panel) and parathyroid
gland (right panel) using an independent RNA probe pair; Ki-67
(MKI67) in anal vulva (left panel) and tonsil (right panel); Platelet
endothelial cell adhesion molecule 1 (PECAM1) in endometrium,
pre menopause (left panel) and lymph node (right panel) using an
independent RNA probe pair; Villin-1 (VIL1) in appendix (left
panel) and duodenum (right panel) using an independent RNA
probe pair. All images were derived from slides scanned with a
406objective.
(TIF)
Figure S4 Representative samples of concordant data
for the novel tissue or cancer specific biomarkers. ISH
signals are seen as blue/purple staining with nuclei counterstained
in methyl green, whereas IHC signals are in brown with
RNA Hybridization on Tissue Microarrays
PLoS ONE | www.plosone.org 6 March 2012 | Volume 7 | Issue 3 | e32927hematoxylin counterstain. Bromodomain containing 1 (BRD1)i n
lung (left panel) and prostate (right panel); Histone-lysine N-
methyltransferase (EZH2) in duodenum (left panel, nuclear and
cytoplasmic staining for protein and mRNA, respectively) and
fallopian tube (right panel, nuclear and cytoplasmic staining for
protein and mRNA, respectively); Junction plakoglobin (JUP)i n
two different tonsil specimens (left and right panel) within the same
TMA; Special AT-rich sequence-binding protein 2 (SATB2) in two
different rectum specimens (left and right panel, nuclear and
cytoplasmic staining for protein and mRNA, respectively) within
the same TMA. All ISH staining were cross validated with an
independent RNA probe pair. All images were derived from slides
scanned with a 406objective.
(TIF)
Figure S5 Representative samples of concordant and
discordant data. ISH signals are seen as blue/purple staining
with nuclei counterstained in methyl green, whereas IHC signals
are in brown with hematoxylin counterstain. Glutamate decar-
boxylase 1 (GAD1) in two different cerebellum specimens (left and
right panel) within the same TMA; Phosphodiesterase 6A (PDE6A)
in two different skeletal muscle specimens (left and right panel)
within the same TMA; Family with sequence similarity 174
member B (FAM174B) in endometrium, postmenopause (left
panel) and stomach (right panel); Janus kinase 3 (JAK3)i n
epididymis (left panel) and breast (right panel) with two
independent RNA probe pairs; v-yes-1 Yamaguchi sarcoma viral
related oncogene homolog (LYN) in appendix (left panel) and
rectum (right panel); Mix1 homeobox-like 1 (MIXL1) in breast (left
panel) and seminal vesicle (right panel); Protein tyrosine
phosphatase type C (PTPRC) in lymph node with two independent
RNA probe pairs (left panel) and in spleen with two independent
RNA probe pairs (right panel); Zinc finger protein 473 (ZNF473)
in rectum (left panel) and tonsil (right panel). All images were
derived from slides scanned with a 406objective.
(TIF)
Table S1 PCR primer sequences used for RNA probe
generation.
(XLS)
Table S2 Primary antibodies used for immunohisto-
chemistry.
(XLS)
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